Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
NCT Number: NCT02018627
This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of Glucagon for Injection (Eli Lilly).
Looking for future studies?
Notify Me21 year–80 year
All sexes
Interventional
Phase 2 / Phase 3
Boston, Massachusetts, 02114, United States
This study will test the hypothesis that micro-doses of a new formulation of stable glucagon, Xerisol Glucagon (Xeris Pharmaceuticals), will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of a freshly reconstituted formulation of glucagon that has poor stability in solution, Glucagon for Injection (Eli Lilly).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The subject is given an injection of xeris glucagon
The subject is given an injection of lilly glucagon
Time frame: every 2 minutes for 1 hour post-dose of each glucagon
tmax for Xeris vs. Lilly (non-inferiority)
Time frame: every 2 minutes for 1 hour post-dose of each glucagon
Area over the curve for glucose infusion rate in the hour following administration (AOCGIR) for Xeris vs. Lilly (non-inferiority)
Time frame: every 2 minutes for 1 hour post-dose of each glucagon
Minimal glucose infusion rate (GIRmin) for Xeris vs. Lilly (non-inferiority)
Time frame: every 2 minutes for 1 hour post-dose of each glucagon
Glucagon t½max for Xeris vs. Lilly (non-inferiority)
Time frame: immediately after injection
Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-average Injection pain on a 10 cm standard VAS: 0 = no pain, 10 = worst imaginable pain reported immediately after injection of glucagon
Time frame: within 1 hour of injection
Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-Injection site erythema or other local reaction, maximum diameter within 1 hour of injection
Time frame: within 1 hour of injection
Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-Maximal nausea within 1 hour of injection on a 10 cm VAS: no nausea = 0, vomiting = 10
Time frame: within 1 hour of injection
Average grade on the erythema and eschar formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)
Time frame: within 1 hour of injection
Average grade on the edema formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)
Steven J. Russell, MD, PhD
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00690066
Autoimmune Diseases, Diabetes Mellitus
Birmingham, Alabama, United States
View Trial DetailsNCT04614168
Autoimmune Diseases, Diabetes Mellitus
Edinburgh, United Kingdom
View Trial DetailsNCT06048757
Autoimmune Diseases, Diabetes Mellitus
Pamplona, Navarre, Spain
View Trial DetailsNCT01747967
Autoimmune Diseases, Diabetes Mellitus
Paris, France
View Trial Details